the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma
the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma
This study was completed in two stages. In the first stage, 2000 participants were enrolled
 according to the criteria. Following the principle of informed consent and voluntary consent
 of patients, the standard operation was "right or bilateral thyroidectomy + isthmus resection
 + right area VI lymph node dissection + left area VI lymph node dissection + lateral neck
 lymph node dissection". The age of participants, the size of right thyroid tumors, the
 invasion of the capsule and the number of lateral neck lymph node metastasis were counted to
 validate and improve the predictive model of lymph node posterior to the right recurrent
 laryngeal nerve in papillary thyroid cancer (Y=-0.029×age+0.771×tumor size+0.660×capsular
 invasion+1.331×right lateral lymph node metastasis-1.687, Y ≥0.16 means right recurrent
 laryngeal nerve posterior lymph node metastasis).

 In the second stage, 2000 participants assessed by the model without posterior right
 recurrent laryngeal nerve metastasis were randomly divided into experimental group and
 control group according to the principle of informed consent and voluntary. The right
 recurrent laryngeal nerve posterior lymph nodes were not dissected in experimental group,
 while the right recurrent laryngeal nerve posterior lymph nodes were routinely dissected in
 control group. Through long-term follow-up and comparison of RFS and OS between the two
 groups, the investigators can scientifically evaluate the effectiveness of the "prediction
 model of lymph node posterior to right recurrent laryngeal nerve metastasis in papillary
 thyroid carcinoma", and seek evidence for accurate treatment of lymph node posterior to the
 right recurrent laryngeal nerve in thyroid papillary carcinoma.
Inclusion Criteria:

 -  Phase I:

 1. aged from 18 years old to 80 years old;

 2. the primary treatment of patients with right or bilateral PTC;

 3. patients will voluntarily enter the study after informed consent.

 Phase II:

 1. aged from 18 years old to 80 years old;

 2. the primary treatment of patients with right or bilateral PTC predicted to have no
 LN-prRLN metastasis by the "prediction model of LN-prRLN";

 3. patients will voluntarily enter the study after informed consent.

 Exclusion Criteria:

 1. patients refused to participate in the study;

 2. non first operation patients;

 3. other malignant tumor history;

 4. distant metastasis;

 5. history of neck trauma.